Akash Tewari
Stock Analyst at Jefferies
Total Price Targets
36
Stocks Covered
21
Sectors
Healthcare
Most Recent
Mar 13, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Akash Tewari
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $1300.00 | $961.67 | +35.2% | 5 | Mar 13, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $103.00 | $54.20 | +90.0% | 2 | Mar 12, 2026 |
| GILD | Gilead Sciences, Inc. | $180.00 | $132.04 | +36.3% | 1 | Mar 10, 2026 |
| AMGN | Amgen Inc. | $350.00 | $328.69 | +6.5% | 1 | Mar 10, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $580.00 | $425.06 | +36.5% | 1 | Mar 10, 2026 |
| APGE | Apogee Therapeutics, Inc. | $95.00 | $81.23 | +17.0% | 1 | Feb 2, 2026 |
| CYTK | Cytokinetics, Incorporated | $90.00 | $64.40 | +39.8% | 2 | Jan 9, 2026 |
| TERN | Terns Pharmaceuticals, Inc. | $70.00 | $52.94 | +32.2% | 1 | Dec 10, 2025 |
| NBIX | Neurocrine Biosciences, Inc. | $174.00 | $131.64 | +32.2% | 1 | Oct 29, 2025 |
| ALKS | Alkermes plc | $56.00 | $33.49 | +67.2% | 3 | Oct 28, 2025 |
| ENTA | Enanta Pharmaceuticals, Inc. | $20.00 | $14.22 | +40.6% | 1 | Oct 1, 2025 |
| BMY | Bristol-Myers Squibb Company | $68.00 | $58.22 | +16.8% | 1 | Apr 23, 2025 |
| MRK | Merck & Co., Inc. | $148.00 | $111.89 | +32.3% | 3 | Nov 15, 2024 |
| EXEL | Exelixis, Inc. | $33.00 | $43.81 | -24.7% | 1 | Oct 15, 2024 |
| RLAY | Relay Therapeutics, Inc. | $16.00 | $12.90 | +24.0% | 2 | Sep 10, 2024 |
| APLS | Apellis Pharmaceuticals, Inc. | $82.00 | $40.95 | +100.2% | 2 | Aug 8, 2024 |
| IONS | Ionis Pharmaceuticals, Inc. | $77.00 | $75.86 | +1.5% | 2 | Jul 22, 2024 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $6.00 | $4.09 | +46.7% | 1 | Jun 18, 2024 |
| REGN | Regeneron Pharmaceuticals, Inc. | $1060.00 | $703.72 | +50.6% | 3 | Apr 12, 2024 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $400.00 | $516.66 | -22.6% | 1 | Mar 15, 2024 |
| ZYME | Zymeworks Inc. | $11.00 | $26.93 | -59.1% | 1 | Dec 19, 2022 |
Recent Activity
- Mar 13, 2026— Set$1300.00price target onLLY(Eli Lilly and Company)
- Mar 12, 2026— Set$103.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Mar 10, 2026— Set$180.00price target onGILD(Gilead Sciences, Inc.)
- Mar 10, 2026— Set$350.00price target onAMGN(Amgen Inc.)
- Mar 10, 2026— Set$580.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Feb 2, 2026— Set$95.00price target onAPGE(Apogee Therapeutics, Inc.)
- Jan 9, 2026— Set$90.00price target onCYTK(Cytokinetics, Incorporated)
- Dec 10, 2025— Set$70.00price target onTERN(Terns Pharmaceuticals, Inc.)
- Oct 29, 2025— Set$174.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Oct 28, 2025— Set$56.00price target onALKS(Alkermes plc)
- Oct 1, 2025— Set$20.00price target onENTA(Enanta Pharmaceuticals, Inc.)
- Jul 15, 2025— Set$95.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Apr 23, 2025— Set$68.00price target onBMY(Bristol-Myers Squibb Company)
- Nov 15, 2024— Set$148.00price target onMRK(Merck & Co., Inc.)
- Oct 15, 2024— Set$33.00price target onEXEL(Exelixis, Inc.)
- Sep 10, 2024— Set$16.00price target onRLAY(Relay Therapeutics, Inc.)
- Aug 15, 2024— Set$147.00price target onMRK(Merck & Co., Inc.)
- Aug 8, 2024— Set$82.00price target onAPLS(Apellis Pharmaceuticals, Inc.)
- Jul 22, 2024— Set$77.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- Jul 16, 2024— Set$75.00price target onIONS(Ionis Pharmaceuticals, Inc.)
Frequently Asked Questions
Who is Akash Tewari?
Akash Tewari is a stock analyst at Jefferies covering 21 stocks primarily in Healthcare. They have issued 36 price targets since Sep 8, 2022.
What stocks does Akash Tewari cover?
Akash Tewari currently covers 21 stocks, including LLY, ALKS, MRK, REGN, BMRN.
What is Akash Tewari's latest price target?
Akash Tewari's most recent price target was $1300.00 on LLY (Eli Lilly and Company), set on Mar 13, 2026.
What is Akash Tewari's highest price target?
Akash Tewari's highest issued price target is $1300.00 on LLY, set on Mar 13, 2026.
More Analysts at Jefferies
Coverage based on publicly published price targets. Not investment advice.